One of the pioneers in messenger RNA vaccines sees limits to their effectiveness against cancers, even after a successful trial raised expectations for the technology.
Tumor-fighting mRNA vaccines will probably be most useful for patients with only a few cancer cells, said Katalin Kariko, a former BioNTech SE executive and University of Pennsylvania researcher whose work helped lay the foundation for the technology’s success in the Covid-19 pandemic.